Pharma POOL

Robert GELBARD
ICN Pharmaceuticals Appoints Former Ambassador to Head International Efforts
Former Ambassador Robert Gelbard joins ICN Pharmaceuticals Inc. as senior VP for international affairs and government relations. Mr. Gelbard is the com pany representative with foreign governments and organizations and with U.S. government agencies and industry trade groups. Mr. Gelbard has held numerous senior positions with the U.S. State Department, most recently serving as U.S. ambassador to Indonesia and East Timor. He served as special representative of the president and the secre tary of state for the Balkans from 1997 until 1999. In that position, he was responsible for all aspects of U.S. government policy develop ment and civilian implementation in the region. Other major positions Mr. Gelbard has held include: U.S. ambassador to Bolivia, assistant secretary of state for International Narcotics and Law Enforcement Affairs, and principal deputy assistant secretary of state for InterAmerican Affairs. Upon his retirement from the State Department in January 2002, Mr. Gelbard was awarded the Secretary’s Dis tinguished Service Award, the State Depart ment’s highest honor, from Secretary of State Colin Powell. Mr. Gelbard joined the Foreign Service in 1967 after serving in the Peace Corps in Bolivia from 1964 to 1966. He graduated from Colby College in 1964 with a B.A. in history, and in 1979 received an MPA in eco nomics from Harvard University. He was awarded an honorary law degree from Villano va University in 1998. For his service as ambassador to Bolivia, Mr. Gelbard was awarded that coun try’s highest honor for foreign citizens, “Con dor of the Andes, Order of the Grand Cross.” “I am proud to have Ambassador Gelbard join ICN Pharmaceuticals,” says Milan Panic, chairman and CEO of Costa Mesa, Calif.based ICN Pharmaceuticals. “He is widely recog nized as a leader in international affairs at the highest level. His experience in Washington affairs also will help ICN enhance its rightful place in the pharmaceutical industry.” Dr. Cecil B. PICKETT Dr. Jonathan R. SPICEHANDLER ScheringPlough Appoints President and Chairman of Research Institute ScheringPlough Corp. has named Cecil B. Pickett, Ph.D., as president of Schering Plough Research Institute (SPRI), with responsibility for all aspects of the institute. In addition, Jonathan R. Spicehandler, M.D., has been appointed chairman of SPRI. In his new position, Dr. Spicehandler, 53, becomes a member of the ScheringPlough operating committee and serves as chief scientific advis er to senior management. Dr. Pickett, 56, joined SPRI in 1993, and most recently was executive VP of discovery research, responsible for the planning, man agement, and oversight of ScheringPlough’s new drugdiscovery programs across all thera peutic areas, and for coordinating those pro grams with other research and commercial components in the company. He came to SPRI from Merck Research Laboratories, Montreal, Canada, and West Point, Pa., where he served as senior VP of basic research. Dr. Pickett has been published extensively in leading research journals and has been a fre quent speaker at scientific symposia and con ferences. He has received several major aca demic awards, appointments, and fellowships and serves on a number of scientific commit tees and editorial boards of medical journals and research organizations. Dr. Pickett serves as a member of the Food and Drug Administration science board, the advisory committee to the director of the National Institutes of Health, and The National Cancer policy board of the Insti tute of Medicine. He was elected to the Institute of Medicine of the National Academy of Sciences in 1993 and also is a member of The American Society for Cell Biology, American Society of Biochemistry and Molecular Biology, American Association for Cancer Research, and American Association for the Advance ment of Science. Dr. Pickett received his B.S. in biology from California State University, Hayward, Calif., and his Ph.D. in cell biology from the University of California, Los Angeles. Dr. Spicehandler joined Kenilworth, N.J. based ScheringPlough in 1982 as senior director, immunology and antiinfective clini cal research. He was appointed VP of clinical research in 1985; VP of biological research in 1991; and VP of operations in 1992. He was named president of SPRI in July 1993. Dr. Spicehandler has authored numerous articles for scientific publications. Dr. Spice handler is a diplomate of the American Board of Internal Medicine and a member of the American College of Physicians and American Society for Clinical Pharmacology and Thera peutics. He is an elected member of the Alpha Omega Alpha Honor Society and serves as president emeritus, board of managers, of the New Jersey division of Cancer Care Inc. Dr. Spicehandler received his B.A. in biol ogy from Union College, Schenectady, N.Y. and his M.D., cum laude, from St. Louis Uni versity School of Medicine, St. Louis. Andrew J. PURCELL Novo Nordisk Names VP of Diabetes Marketing in the U.S. Andrew J. Purcell has joined Novo Nordisk Pharmaceuticals Inc. as VP of diabetes marketing, directing the strategy, branding, and execution of marketing programs for the company’s compre hensive line of diabetes care products. Mr. Purcell also serves as a mem ber of the executive team. “Andrew’s depth of experience complements our management team,” says Martin Soeters, president of Novo Nordisk, with U.S. offices in Princeton, N.J. “His background includes TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY TALENT pool more than 18 years of progressive experience in the pharmaceutical industry and broad exper tise in marketing and sales. These qualities, combined with his leadership abilities, enable Andrew to guide our marketing efforts as we extend our presence in the diabetes market.” Before joining Novo Nordisk, Mr. Purcell was VP of marketing and sales with Tredegar Biotech, a division of Tredegar Corp. There he was responsible for prelaunch marketing and commercial planning for a number of pharma ceutical and tissueengineered products. Mr. Purcell has a master’s degree in busi ness administration from the University of Western Ontario, Canada, which included one term at The Business School, Delft, The Netherlands. He received a bachelor’s degree from the University of British Columbia, where he studied microbiology. Robert SAVAGE Industry Veteran Heads Pharmacia’s Global Prescription Business Bringing more than 25 years of experience in the pharmaceutical industry, Robert Savage joins Pharmacia Corp. as group VP and presi dent of general therapeutics and inflammation business. In this key role within the company’s glob al prescription business group, Mr. Savage is responsible for Pharmacia’s arthritis and inflammation portfolio led by Celebrex, the cornerstone of the Peapack, N.J.based compa ny’s COX2 inhibitor platform. Mr. Savage has worked in a diverse range of executive positions, including sales, market ing, product management, business develop ment, strategic planning, and general man agement. Most recently, he served as worldwide chairman of Johnson & Johnson’s pharmaceutical group, a business with more than $14 billion in annual sales. “We are very pleased to have Bob join Pharmacia to maximize the pipeline and prod uct opportunities in our global arthritis and inflammation business,” says Carrie Cox, exec utive VP and president of the Global Pre scription Business. “Bob joins us at an exciting juncture as we build on the leadership position we have established in the coxib arena with this year’s launches of Bextra and Dynastat.” Mr. Savage earned a MBA from Rutgers University in 1984 and holds a B.S. from Upsala College in East Orange, N.J. Biotech POOL Dr. Bryan T. BUTMAN Dr. Henrik S. RASMUSSEN Mary P. SUNDEEN Robert S. TENEROWICZ GenVec Announces SeniorLevel Promotions GenVec Inc. has announced several promo tions as the company moves closer to product commercialization. Among those promoted are Henrik S. Rasmussen, M.D., Ph.D., to senior VP of clinical research and regulatory affairs; Bryan T. Butman, Ph.D., to VP of qual ity; Mary P. Sundeen to VP of corporate com munications; and Robert S. Tenerowicz to VP of process development and clinical supplies. 103 PharmaVOICE M a y / J u n e 2 0 02 Dr. Shirley TILGHMAN The jury of the For Women In Science Awards, now in its third year and sponsored by L’Oreal and UNESCO, has selected Dr. Shirley M. Caldwell Tilghman, president of Princeton University, as the North American laureate. A distinguished molecular biologist and respected member of the American Philosophical Society, the National Academy of Sciences, the Institute of Medicine and the Royal Society of London, Dr. Tilghman has been a vocal advocate on behalf of women in science. She was a leading architect of the national effort to map the human genome. In the 1970s she was a member of the first research team to isolate mammalian genes. In May 2001, Dr. Tilghman was named pres ident of Princeton University and is now among three women leading Ivy League institutions in the U.S. Dr. Tilghman, originally from Toronto, is one of five distinguished laureates from around the world — representing Europe, Africa, North America, South America, and Asia — selected by the international jury panel, who were awarded the prestigious For Women In Science Award at the ceremony held in Paris in March. Other winners were Dr. Nagwa A. Meguid, professor of human genetics at the National Research Center in Cairo, Egypt; Dr. Ana Maria Lopez Colome, professor of neuroscience and biochemistry at The Institute of Cellular Physiology, National Autonomous University, Mexico City, Mexico; Dr. Mary Osborn, a pioneer of immunofluores cence microscopy from Max Planck Institute of Biophysical Chemistry, Gttingen, Germany; and Dr. Indira Nath, an internationally renowned authority on leprosy, from the All India Institute of Medical Sciences, New Delhi, India. “It is an honor to have been chosen for this award,” Dr. Tilghman says. “In my 25 years as a biologist, I have seen significant growth in the opportunities for women to pursue careers in science. However, many challenges remain. The world is full of fascinating and urgent scientific questions, and I hope this award inspires young women to pursue them. We still live in a world in which science is large ly a male profession. If this is ever going to change, it is going to have to change in the minds of young women who are thinking about what they are going to do with their lives. The more that they can see that there are women who are in the profession, and succeeding in the profession, the more like ly in 25 years there will be as many women as men succeeding in science.” Last year’s North American Laureate, Dr. Joan Steitz, a Sterling pro fessor at Yale University and a member of this year’s jury panel, says, “Dr. Tilghman is a terrific scientist whose groundbreaking research has led to a molecular understanding of why the outcome can be different when a mutant gene is inherited from the mother rather than the father. This has been instrumental in clarifying the patterns of inheritance of certain cancers and other genetic disorders. She has not only champi oned the cause of women in science but has been a vocal advocate for bettering the welfare of young scientists in general. Her willingness to take on a challenge — small or large, social or scientific — and invari ably come up with innovative solutions has always commanded my greatest respect.” Since the awards were created, the For Women In Science Awards have been credited with highlighting the enormous contributions made by women in science all over the world and with underscoring the importance of encouraging young women to pursue careers in science. Dr. Shirley M. Caldwell Tilghman hopes that programs such as the For Women in Science Awards will inspire young women to pursue careers in science. Dr. Shirley M. Caldwell Tilghman hopes that programs such as the For Women in Science Awards will inspire young women to pursue careers in science. PRINCETON UNIVERSITY PRESIDENT SELECTEDTO RECEIVE FORWOMEN IN SCIENCE AWARD TALENT pool “GenVec is moving toward product com mercialization with product candidates in human clinical trials for coronary artery dis ease, peripheral vascular disease, and a variety of cancers,” says Dr. Paul H. Fischer, president and CEO of Gaithersburg, Md.based GenVec. “We are pleased with the clinical results on these genebased medicines, BioBypass and TNFerade. Progress in the clinic has led to expanded needs in manufacturing, regulatory affairs, process development, and communica tions.” Before joining GenVec in April 1999 as VP for clinical and regulatory affairs, Dr. Ras mussen spent four years as VP for clinical research/senior VP for clinical research and regulatory affairs at British Biotech in Annapolis, Md., and was responsible for North American clinical operations. Dr. Ras mussen has been involved in drug develop ment in a number of different therapeutic areas, including cardiology, oncology, inflam mation, acute care, neurology, and dermatolo gy and has published more than 130 scientif ic papers and abstracts. Dr. Rasmussen received his M.D. and Ph.D. from the University of Copenhagen and spent four years practicing medicine at Hvi dovre University Hospital in Copenhagen, part of the Copenhagen School of Medicine. Dr. Butman joined GenVec in 1999, and served as director of quality and analytical sci ences, before being promoted to VP of quality. Dr. Butman brings more than 16 years of expe rience in the development, clinical testing, reg istration, and manufacture of medical diagnos tic products and development of quality control assays for parenteral biopharma ceuticals. Throughout his career, Dr. Butman has developed successful diag nostic products in the areas of cardiovas cular disease (coronary risk markers), oncology (clinical laboratory and point ofcare tests), infectious disease (virology, microbiology, food safety), and hematol ogy. He has held senior positions within Warner Lambert, AkzoNobel, Organon Teknika, PerImmune, and Intracel. Dr. Butman holds a Ph.D. in Cell Biology from Wayne State University. Ms. Sundeen joined GenVec in May 2001 as executive director of corporate communications, bringing 20 years of public and media relations experience to the company. Before GenVec, Ms. Sun deen served as senior director of corpo rate communications and investor rela tions for publicly held EntreMed Inc., where she directed communications and crisis management efforts around the company’s widely publicized anticancer compounds. At GenVec, Ms. Sundeen serves as corporate spokesperson and is responsible for public and media rela tions, investor relations, public policy, 104 M a y / J u n e 2 0 0 2 PharmaVOICE Joseph A. ESPOSITO Joseph A. Esposito, president and CEO of eRe searchTechnology Inc. — a Philadelphiabased provider of technology and services to the pharma ceutical and medical device industries — has been awarded the Ellis Island Medal of Honor for out standing citizenship, individual achievement, and encouragement of cultural unity. The medals are presented each year by The National Ethnic Coalition of Organizations Inc., which was formed with the intention of educating and encouraging cultural unity. Designed to pay homage to the immigrant experience, as well as individual achievement, medals are awarded to U.S. citizens from various ethnic backgrounds. The honorees are remarkable Americans who exemplify outstanding qualities in both their per sonal and professional lives, while continuing to preserve the richness of their particular heritage. The Ellis Island Medal of Honor was creat ed in 1986 to honor the many ancestral groups who through struggle, sacrifice and success, helped build the U.S. Four presidents, several senators and congressman and Nobel Prize winners are among the group of individuals to receive the Ellis Island Medal of Honor for their outstanding contributions to America. The Ellis Island Medal of Honor celebrates the richness and diversity of American life. The award honors not only individuals but also the pluralism and democracy that has enabled each group to maintain their identities while becoming integral parts of the American way of life. Congress sanctions the Ellis Island Medal of Honor and recipients’ names are list ed in the congressional record. The Ellis Island Medals of Honor were pre sented at the gala event on Ellis Island on May 11, 2002. ERESEARCH PRESIDENT HONORED FOR OUTSTANDING CITIZENSHIP, ENCOURAGEMENT OF CULTURAL UNITY and crisis management. She received her B.A. from the State University of New York and has subspecialty training in technical writing and biomedical communication. Mr. Tenerowicz joined GenVec in 1997 and has more than 16 years of productdevel opment experience in the biotechnology industry. He most recently served as senior director of product management for GenVec. Before joining GenVec, Mr. Tenerowicz led the project management function at Cell Genesys Inc. Mr. Tenerowicz has a B.S. in physiology from the University of California at Davis and a MBA in operations manage ment from Golden Gate University. Brooks ENSIGN Dr. Dominick VACANTE Ceregene Announces Additions to Management Team Ceregene Inc., a biotechnology company focused on gene therapies for neurological dis orders such as Alzheimer’s disease and Parkin son’s disease, has appointed two new members to its management team. Brooks Ensign has joined Ceregene as director of business development. Mr. Ensign recently served as director of business develop ment with Aviva Biosciences, where he led fundraising, technology licensing, and public relations programs. His previous positions included negotiating international pharma ceutical acquisitions at ICN Pharmaceuticals and supporting the launch of two novel biotechnology products with Advanced Tissue Sciences. Mr. Ensign holds a MBA from Har vard Business School. Dominick Vacante, Ph.D., has joined Cere gene as senior director of product development. Dr. Vacante has 13 years of experience in the manufacturing of biotechnology products and has extensive knowledge of the development and manufacturing of viral genedelivery sys tems in the GLP/GMP environment. Before joining Ceregene, he was director of research and development at BioReliance Inc. where he was a founder of its viral vector manufacturing operation. Dr. Vacante holds a Ph.D. in biochemistry and completed postdoctoral training in molecular biology. Ceregene, located in San Diego, was launched in January 2001 as a majorityowned subsidiary of Cell Genesys Inc., based in Fos ter City, Calif. Dr. John M.FARAH Robert KNECHT Cephalon Announces Executive Appointments in Business Development and IT Cephalon Inc. has appointed two of its executives to new positions — John M. Farah, Ph.D., to VP of worldwide business develop ment, and Robert Knecht to VP of informa tion technology and services. In his new role, Dr. Farah is responsible Pharma POOL Robert Gelbard, ICN Pharmaceuticals Dr. Cecil B. Pickett, Schering-Plough Corp. Dr. Jonathan R. Spicehandler, Schering-Plough Corp. Andrew J. Purcell, Novo Nordisk Robert Savage, Pharmacia Corp. Biotech POOL Dr. Bryan T. Butman, GenVec Inc. Dr. Henrik S. Rasmussen, GenVec Inc. Mary P. Sundeen, GenVec Inc. Robert S. Tenerowicz, GenVec Inc. Brooks Ensign, Ceregene Inc. Dr. Dominick Vacante, Ceregene Inc. Dr. John M. Farah, Cephalon Inc. Robert Knecht, Cephalon Inc. Dr. Bruce D. Given, Texas Biotechnology Corp. Specialty POOL Larry K. Tamura, Atrix Laboratories Inc. Genomics POOL Dr. Annie Fong, Exelixis Inc. Dr. Harold Keer, Exelixis Inc. Kimberly J. Manhard, Exelixis Inc. Russell L. Allen, Cellular Genomics Inc. Michael A. Nemzek, Aspira Biosystems Inc. Drug Development/Discovery POOL Dr. Navin Chandra, GenStruct Inc. Dr. Jeffrey D. Thomas, GenStruct Inc. Device/Diagnostics POOL C. Boyd Clarke, Neose Technologies Inc. Jeffrey Jones, Quidel Corp. Emerging POOL Dr. James E. Barrett, Memory Pharmaceuticals Corp. Dr. Richard L. Jackson, EmerGen Inc. F. David King, Medinox Inc. Mark Leuchtenberger, Therion Biologics Corp. Dr. Flossie Wong-Staal, Immusol Service POOL Guy M. Amato, Access Worldwide Communications Inc. Lee Edelstein, Access Worldwide Communications Inc. Shawkat Raslan, Access Worldwide Communications Inc. Bob Atlas, The Lewin Group Dr. Jacqueline Brooks, ApotheCom Associates LLC Mark Dana, ApotheCom Associates LLC Dr. Kate Mann, ApotheCom Associates LLC Laura Marks, ApotheCom Associates LLC Karen Oberheim, ApotheCom Associates LLC Lisa Buechler, Quovadx Inc. David Nesvisky, Quovadx Inc. Hensley Evans, Harte-Hanks Inc. Frank Harvey, Harte-Hanks Inc. Donna Fucello, Medicalliance Inc. Mona T. Quinn, Medicalliance Inc. Eric Meyers, 3rd Millennium Dr. Marie Savard, Medical ­Broadcasting Company Media POOL Cory Coleman, Advanstar Healthcare Marc DiBartolomeo, Advanstar Healthcare Robert Fontenelli, Newton Interactive Inc. Dr. Howard Franklin, Newton Interactive Inc. Janice Theobald, International Medical News Group Agency POOL Barry Brandstetter, Gerbig, Snell/­Weis­heimer & Associates Loring Cloud, Gerbig, Snell/­Weis­heimer & Associates Jamie Cobb, Gerbig, Snell/­Weis­heimer & Associates Neal Gearinger, Gerbig, Snell/­Weis­heimer & Associates John Jakovlic, Gerbig, Snell/­Weis­heimer & Associates Vicki Miller, Gerbig, Snell/­Weis­heimer & Associates Jennifer Peters, Gerbig, Snell/­Weis­heimer & Associates Dan Smith, Gerbig, Snell/­Weis­heimer & Associates Terri Spring, Gerbig, Snell/­Weis­heimer & Associates Robert Doody, Dorland Sweeney Jones Health Communications Amy Gerber, Dorland Sweeney Jones Health Communications Kevin Huang, Dorland Sweeney Jones Health Communications Kelcey King, Dorland Sweeney Jones Health Communications Liv Mansfield, Dorland Sweeney Jones Health Communications Julie Morse, Dorland Sweeney Jones Health Communications Carmen Johnson, The Medical Education Group Rhea Juntereal, The Medical Education Group Irene McKnight-­Durham, The Medical Education Group Elizabeth Rosenberg, The Medical Education Group Michael Raffin, The Medical Education Group R. Steven Lang, DVC Worldwide Dr. Julia Ralston, DVC Worldwide

Download PDF